Scientific Conferences | Galecto

Past Events

Dec 10 - Dec 13, 2022	ASH Annual Meeting 2022 Poster title: MYLOX-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis: Intermediate Assessment Poster audio recording: MYLOX-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis: Intermediate Assessment https://www.hematology.org/meetings/annual-meeting
Nov 8, 2022	Galecto GULLIVER-2 Call Supporting Materials Galecto GULLIVER-2 Webcast Presentation 4.4 MB
Nov 4 - Nov 8, 2022	AASLD 2022 Abstract title: GB1211, an oral galectin-3 inhibitor, in decompensated cirrhotic patients: initial findings from the Phase 2 randomized, placebo-controlled GULLIVER-2 trial (late-breaking oral presentation) Poster title: GULLIVER-2 is an innovative, hybrid, hepatic impairment trial of the oral galectin-3 inhibitor GB1211 (poster presentation) Poster title: The novel galectin-3 inhibitor GB1211 reduces inflammation & fibrosis in a rabbit high fat diet model of NASH & fibrosis (late-breaking poster presentation) https://www.aasld.org/the-liver-meeting
Jun 3 - Jun 7, 2022	ASCO Conference Poster title: GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC) – a randomized double-blind trial Poster title: Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1 https://beta.asco.org/
May 13 - May 18, 2022	ATS 2022 Poster title: DEFINE - a Randomized, Open-Label Trial of the Inhaled Galectin-3 Inhibitor GB0139 in Hospitalized Patients with Moderate-to-Severe COVID-19 https://conference.thoracic.org/